Skip to main content

Table 2 Treatment response to cetuximab-based chemotherapy

From: Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma

 

Total

Locoregional recurrence

Distant metastasis

p-value

(n = 104)

(n = 61)

(n = 40)

Treatment Response

   

0.169

 CR

1 (1.0%)

1 (1.6%)

0 (0.0%)

 

 PR

34 (32.7%)

22 (34.4%)

12 (30.0%)

 

 SD

24 (23.1%)

18 (28.1%)

6 (15.0%)

 

 PD

45 (43.3%)

23 (35.9%)

22 (55.0%)

 

 ORR

35 (33.7%)

23 (35.9%)

12 (30.0%)

0.533

 DCR

59 (56.7%)

41 (62.5%)

18 (45.0%)

0.056

  1. Abbreviations: CR complete response, PR partial response SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate. The tumor response of 3 patients could not be assessed. Data are presented with median (IQR) or n (%). Bold indicates statistically significant at p < 0.05